A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations (ESMO 2025)

Publication

October 19, 2025

Iambic Announces Pricing of Initial Public Offering

Publication

October 14, 2026

Iambic Announces Pricing of Initial Public Offering

Publication

October 5, 2026

Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate

Publication

September 21, 2026

Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development

Let's work together

Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.